{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:25:11Z","timestamp":1789140311218,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["YG2025ZD22"],"award-info":[{"award-number":["YG2025ZD22"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["YG2026LC16"],"award-info":[{"award-number":["YG2026LC16"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2025ZD01903302"],"award-info":[{"award-number":["2025ZD01903302"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3501905"],"award-info":[{"award-number":["2022YFC3501905"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2060302"],"award-info":[{"award-number":["2060302"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473851"],"award-info":[{"award-number":["82473851"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.115032","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:30:47Z","timestamp":1779219047000},"page":"115032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["STING agonist-primed supramolecular oncolytic hydrogel vaccine for tuning tumors against themselves"],"prefix":"10.1016","volume":"395","author":[{"given":"Mingmei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115032_bb0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41551-019-0503-3","article-title":"A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia","volume":"4","author":"Shah","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115032_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrclinonc.2017.149","article-title":"Cancer vaccines on the move","volume":"15","author":"Banchereau","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115032_bb0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41563-020-0793-6","article-title":"A DNA nanodevice-based vaccine for cancer immunotherapy","volume":"20","author":"Liu","year":"2021","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.115032_bb0025","doi-asserted-by":"crossref","first-page":"eabc2816","DOI":"10.1126\/scitranslmed.abc2816","article-title":"Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines","volume":"13","author":"Chen","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115032_bb0030","doi-asserted-by":"crossref","first-page":"35385","DOI":"10.1021\/acsnano.5c06278","article-title":"Virus-like particle-based personalized neoantigen Nano-vaccine for tumor immunotherapy and recurrence prevention","volume":"19","author":"Zhou","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115032_bb0035","doi-asserted-by":"crossref","first-page":"114429","DOI":"10.1016\/j.jconrel.2025.114429","article-title":"Engineered potent DC vaccine enables closer DC-T cell contact to trigger personalized antitumor immunity","volume":"389","author":"Sun","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115032_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2025.102840","article-title":"Intranasal hybrid vesicles delivering personalized in situ nano-vaccines induce glioblastoma remodeling to sensitize immunotherapy","volume":"65","author":"Wang","year":"2025","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2026.115032_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41588-023-01349-3","article-title":"Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements","volume":"55","author":"Shah","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jconrel.2026.115032_bb0050","article-title":"Potential tumor-specific antigens and immune landscapes identification for mRNA vaccine in thyroid cancer","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115032_bb0060","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","article-title":"A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy","volume":"15","author":"Xu","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0065","article-title":"Identification of novel tumor antigens and the immune landscapes of bladder Cancer patients for mRNA vaccine development","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0075","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1150","article-title":"Cancer vaccines: between the idea and the reality","volume":"3","author":"Finn","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0080","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acsnano.1c11562","article-title":"Trauma-responsive scaffold synchronizing oncolysis immunization and inflammation alleviation for post-operative suppression of Cancer metastasis","volume":"16","author":"Li","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115032_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.47","article-title":"The oncolytic peptide LTX-315 triggers immunogenic cell death","volume":"7","author":"Zhou","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2026.115032_bb0090","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1021\/acs.jmedchem.5b02025","article-title":"Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide","volume":"59","author":"Haug","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115032_bb0095","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.4155\/fmc-2017-0088","article-title":"LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment","volume":"9","author":"Sveinbjornsson","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115032_bb0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and tolerogenic cell death","volume":"9","author":"Green","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0105","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/d41586-024-01429-2","article-title":"Vaccinating against cancer from inside the tumour","volume":"629","author":"Drew","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115032_bb0110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115032_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202411330","article-title":"Intratumoral injectable redox-responsive immune niche improves the abscopal effect in radiotherapy","volume":"37","author":"Au","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.115032_bb0120","article-title":"A universal therapeutic vaccine leveraging autologous pre-existing immunity to eliminate in situ uniformly engineered heterogeneous tumor cells","volume":"37","author":"Wu","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.115032_bb0125","doi-asserted-by":"crossref","first-page":"eado5937","DOI":"10.1126\/sciimmunol.ado5937","article-title":"Linking vaccine adjuvant mechanisms of action to function","volume":"10","author":"Ben-Akiva","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0130","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.immuni.2024.03.015","article-title":"Vaccine adjuvants: tailoring innate recognition to send the right message","volume":"57","author":"Lavelle","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115032_bb0135","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","article-title":"Regulatory T cells in the tumour microenvironment","volume":"25","author":"Imianowski","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115032_bb0140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0145","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41565-020-00843-7","article-title":"Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection","volume":"16","author":"Zhang","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0150","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115032_bb0155","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115032_bb0160","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115032_bb0165","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115032_bb0170","doi-asserted-by":"crossref","first-page":"114731","DOI":"10.1016\/j.jconrel.2026.114731","article-title":"Co-delivery of a STING agonist and indoleamine 2, 3-dioxygenase 1 blockade activates type I dendritic cells in cancer","volume":"392","author":"Xia","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115032_bb0175","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8(+) T cell responses through CD8 alpha(+) dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115032_bb0180","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41392-022-01252-z","article-title":"Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115032_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114020","article-title":"Delivery of STING agonists for adjuvanting subunit vaccines","volume":"179","author":"Van Herck","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115032_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201703444","article-title":"Self-assembled peptide-based nanomaterials for biomedical imaging and therapy","volume":"30","author":"Qi","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.115032_bb0195","doi-asserted-by":"crossref","first-page":"13165","DOI":"10.1021\/acs.chemrev.5b00299","article-title":"Supramolecular hydrogelators and hydrogels: from soft matter to molecular biomaterials","volume":"115","author":"Du","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.115032_bb0200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","article-title":"In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0205","article-title":"A zwitterionic polyurethane nanoporous device with low foreign-body response for islet encapsulation","volume":"33","author":"Liu","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.115032_bb0210","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41551-020-0597-7","article-title":"Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel","volume":"4","author":"Wang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115032_bb0215","doi-asserted-by":"crossref","first-page":"10651","DOI":"10.1021\/acsnano.3c01748","article-title":"Supramolecular filament hydrogel as a universal immunomodulator carrier for immunotherapy combinations","volume":"17","author":"Wang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115032_bb0220","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1021\/acsnano.0c03286","article-title":"Supramolecular tubustecan hydrogel as chemotherapeutic carrier to improve tumor penetration and local treatment efficacy","volume":"14","author":"Wang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115032_bb0225","article-title":"Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115032_bb0230","article-title":"Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115032_bb0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jconrel.2020.01.003","article-title":"Self-assembling and self-formulating prodrug hydrogelator extends survival in a glioblastoma resection and recurrence model","volume":"319","author":"Schiapparelli","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115032_bb0240","doi-asserted-by":"crossref","first-page":"283ra252","DOI":"10.1126\/scitranslmed.aaa4306","article-title":"STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade","volume":"7","author":"Fu","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115032_bb0245","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2026.115032_bb0250","article-title":"Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection","volume":"14","author":"D'Alise","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115032_bb0255","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41565-019-0512-0","article-title":"Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators","volume":"14","author":"Conniot","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121565","article-title":"Advanced nanomedicines for the regulation of cancer metabolism","volume":"286","author":"Yang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115032_bb0265","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","article-title":"The role of ROS in tumour development and progression","volume":"22","author":"Cheung","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115032_bb0270","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115032_bb0275","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115032_bb0280","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","article-title":"Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity","volume":"25","author":"Sivick","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2026.115032_bb0285","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/32183","article-title":"Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs","volume":"392","author":"Albert","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115032_bb0290","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115032_bb0295","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41565-020-00782-3","article-title":"Proton-driven transformable nanovaccine for cancer immunotherapy","volume":"15","author":"Gong","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115032_bb0305","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:17:40Z","timestamp":1783145860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":60,"alternative-id":["S0168365926004359"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115032","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STING agonist-primed supramolecular oncolytic hydrogel vaccine for tuning tumors against themselves","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115032"}}